Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661387 | 1.00 | CASP1 (0.44) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL1417549 | 1.00 | CASP1 (0.44) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL4596673 | 0.94 | KMT2A (0.42) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL11276948 | 0.87 | KMT2A (0.50) | KMT2AALDH1A1 | |
| SCHEMBL9535176 | 0.86 | CXCL8 (0.46) | ABCB11ALDH1A1 | |
| SCHEMBL5327049 | 0.83 | CASP1 (0.56) | CASP1CYP2C19KMT2AALDH1A1 | |
| SCHEMBL30296727 | 0.82 | CA12 (0.43) | CASP1CYP2C19KMT2AALDH1A1HIF1A | |
| SCHEMBL26620210 | 0.82 | CA12 (0.43) | CASP1CYP2C19KMT2AALDH1A1HIF1A | |
| SCHEMBL6487230 | 0.81 | ALDH1A1 (0.56) | CASP1ABCB11THRBNR1I2CHRM2 | |
| SCHEMBL30065589 | 0.80 | NR3C2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655652-A | New synthesis method of clopidogrel | 宿迁盛基医药科技有限公司 | 2023-08-29 | — | — | CN | claimed |
| CN-112892204-B | Automobile indoor VOC remover and preparation method thereof | 烟台大学 | 2022-04-01 | — | — | CN | claimed |
| CN-112892204-A | Automobile indoor VOC remover and preparation method thereof | 烟台大学 | 2021-06-04 | — | — | CN | claimed |
| CN-108246099-B | Automobile indoor VOC remover and preparation method thereof | 烟台大学 | 2021-02-09 | — | — | CN | claimed |
| CN-1293080-C | Process for the preparation of clopidogrel | DIPHARMA SPA (IT) | 2007-01-03 | — | — | CN | claimed |
| CN-1649877-A | Process for the preparation of clopidogrel | DIPHARMA SPA (IT) | 2005-08-03 | — | — | CN | claimed |
| CN-110300744-B | Compounds for optically active devices | 爱尔兰眼力健公司 | 2023-09-15 | — | — | CN | disclosed |
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753387-B2 | Compounds for optically active devices | Johnson & Johnson Surgical Vision, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-116655652-A | New synthesis method of clopidogrel | 宿迁盛基医药科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-3889135-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3889135-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-08-02 | — | — | EP | disclosed |
| US-5260285-A | Substituted imidazopyridazines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1993-11-09 | — | — | US | disclosed |
| US-5250521-A | Administering in treatment of eleuated blood pressure, conjestive heart failure and ocular hypertension | MERCK & CO., INC. (US) | 1993-10-05 | — | — | US | disclosed |
| US-5177095-A | Hypotensive agents | MERCK & CO., INC. (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0515535-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | disclosed |
| EP-0490587-A1 | Substituted pyrazolopyrimidines and imidazopyridazines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| WO-1991012001-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| WO-1991011909-A1 | TRIAZOLE ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753387-B2 | Compounds for optically active devices | PDE6C, PDE6A, PDE6D | CASP1 2797/4885ABCB11 3968/4885THRB 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.